Kailera Therapeutics, Inc. Shareholders' Equity
Kailera Therapeutics, Inc. (KLRA) had Shareholders' Equity of $1.12 billion as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-12
- 2026-06-30: Stockholders' Equity Attributable to Parent $1.12B.
- 2026-03-31: Stockholders' Equity Attributable to Parent -$432.09M.
- 2025-12-31: Stockholders' Equity Attributable to Parent -$356.46M.
- 2025-06-30: Stockholders' Equity Attributable to Parent -$262.58M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $1.12B 10-Q · filed 2026-08-12 |
| 2026-03-31 | -$432.09M 10-Q · filed 2026-08-12 |
| 2025-12-31 | -$356.46M 10-Q · filed 2026-08-12 |
| 2025-06-30 | -$262.58M 10-Q · filed 2026-08-12 |
| 2025-03-31 | -$235.24M 10-Q · filed 2026-08-12 |
| 2024-12-31 | -$218.77M 10-Q · filed 2026-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |